Omnicare Clinical Research announced today that it has expanded its global footprint to include an office in Sweden.
OMNICARE CLINICAL RESEARCH OPENS OFFICE IN SWEDEN
King of Prussia, PA-11 August 2008-Omnicare Clinical Research announced today that it has expanded its global footprint to include an office in Sweden. The office is located at Kista Science Tower, Unit B1272, Färögatan 33, 164 51 Kista, Sweden.
“Omnicare Clinical Research continues to expand its worldwide presence through the opening of this new Swedish facility,” said Dr. Dale Evans, President and CEO. “We are committed to the Scandinavian marketplace, where we already have offices in Denmark and Finland. We’re looking forward to future growth and continued success with our partners in the region.”
About Omnicare Clinical Research
Headquartered in King of Prussia, PA, Omnicare Clinical Research provides clinical
development services to pharmaceutical, biotechnology and medical device companies through
its office locations in 31 countries worldwide. As a premier Phase I-IV contract research
organization, Omnicare Clinical Research features diverse therapeutic expertise and a
comprehensive scope of clinical service offerings. Additionally, the company is an industry
leader in geriatrics-focused drug studies. Omnicare Clinical Research focuses on providing clients with a superior drug development experience through strong project management, exceptional service and proactive solutions. The company is a subsidiary of Omnicare, Inc., a leading provider of pharmacy services to long-term care facilities and other chronic care settings comprising nearly 1.4 million beds in 47 states (NYSE: OCR).
www.OmnicareCR.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.